gsk201410076k.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending October 2014
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
In accordance with DTR 3.1.4 R(1)(a) and (c) GlaxoSmithKline plc ('GSK') was advised on 7 October 2014 that the following acquisitions of GSK Ordinary shares took place on 6 October 2014, at a price of 1440.375 pence per Ordinary share, following the re-investment of dividends on shares held within an ISA:
|
Director/PDMR
|
Number of Ordinary shares
|
|
Sir Andrew Witty
|
108
|
|
Mr D S Redfern
|
20
|
|
Mrs V A Whyte
|
17
|
|
Connected person
|
Number of Ordinary shares
|
|
Lady C Witty
|
21
|
V A Whyte
Company Secretary
7 October 2014
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: October 07, 2014
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc